Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of BI 1467335 in Healthy Males
NCT03382509Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C]-Radioactivity Excreted in Urine and Fraction of [14C]-Radioactivity Excreted in Faeces. Started Jan 2018; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03382509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382509.